Navigation Links
Cardium Exhibiting Its New FDA-Cleared Excellagen® At The 2012 Spring Symposium Of Advanced Wound Care

SAN DIEGO, April 19, 2012 /PRNewswire/ -- Cardium Therapeutics (NYSE Amex: CXM) is currently exhibiting its new FDA-cleared Excellagen® professional-use, syringe-based wound care product for the management of diabetic foot ulcers, pressure ulcers and other dermal wounds at the 2012 Spring Symposium on Advanced Wound Care (SAWC) being held April 19 - 22, 2012 in Atlanta, GA.


The 2012 Spring SAWC provides Cardium an opportunity to showcase its Excellagen high molecular weight formulated fibrillar collagen-based topical gel to the more than 2,000 attendees including physicians, podiatrists, nurses, therapists and researchers. Medical professionals can learn more about Excellagen by visiting us at Booth 247 or contacting Sarah Dennison at

About Excellagen
Excellagen is a highly-refined fibrillar collagen-based topical gel (2.6%) designed to support favorable wound care management.  Excellagen's unique high molecular weight bovine Type I collagen formulation is topically applied through easy-to-control, pre-filled single use syringes. Excellagen is intended for physician use following surgical debridement procedures, and is engineered to support a favorable wound healing environment for non-healing lower extremity ulcers in diabetic patients.  Excellagen's viscosity optimized biocompatible gel formulation requires application at only one or two week intervals. It is recommended that Excellagen be applied following surgical debridement in the presence of blood cells and platelets, which are involved with the release of endogenous growth factors.

Cardium's market research indicates that physicians seek easy-to-use products to reduce preparation time and facilitate product application - and Excellagen's ready-to-use syringe-based collagen gel requires no thawing or mixing.  In addition, because of its specialized formulation, only a thin layer needs to be applied over the wound area, and one syringe containing 0.5 cc of Excellagen covers wounds up to 5cm2 in size using the supplied 24-gauge single-use flexible applicator tip.  To learn more about Excellagen and for product ordering information, please visit and view the informational YouTube video, Excellagen: A New Wound Care Pathway for Diabetic Foot Ulcers, at            

About Cardium
Cardium is a health sciences and regenerative medicine company focused on the acquisition and strategic development of new and innovative bio-medical product opportunities and businesses with the potential to address significant unmet medical needs that have definable pathways to commercialization, partnering and other economic monetizations.  Cardium's current medical opportunities portfolio, which is focused on health sciences and regenerative medicine, includes the Tissue Repair Company, Cardium Biologics, and the Company's in-house MedPodium® Health Sciences healthy lifestyle product platform.  The Company's lead commercial product Excellagen topical gel for wound care management, has recently received FDA clearance for marketing and sale in the United States.  Cardium's lead clinical development product candidate Generx® is a DNA-based angiogenic biologic intended for the treatment of patients with myocardial ischemia due to coronary artery disease.  In addition, consistent with its capital-efficient business model, Cardium continues to actively evaluate new technologies and business opportunities.  In July 2009, Cardium completed the sale of its InnerCool Therapies medical device business to Royal Philips Electronics, the first asset monetization from the Company's biomedical investment portfolio. News from Cardium is located at

Forward-Looking Statements
Except for statements of historical fact, the matters discussed in this press release are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from stated expectations.  For example, there can be no assurance that we can successfully introduce Excellagen into wound care markets for the treatment of diabetic foot ulcers or other dermal wounds; that awareness of and interest in Excellagen can be effectively enhanced through professional symposia or otherwise; that we can have Excellagen or our other products manufactured in a successful and cost-effective manner; that we can attract suitable commercialization partners for our products or that such partners will successfully commercialize our products; that our exchange listing compliance can be maintained; that our product or product candidates will not be unfavorably compared to other competitive products that may be regarded as safer, more effective, easier to use or less expensive; that results or trends observed in one clinical study or procedure will be reproduced in subsequent studies or procedures or in actual use; that efforts to broaden commercialization of Excellagen outside of the United States will be successful; that clinical studies and regulatory clearances even if successful will lead to product advancement or partnering; that that FDA or other regulatory clearances or other certifications, or other commercialization efforts will effectively enhance our businesses or their market value; that our products or product candidates will prove to be sufficiently safe and effective after introduction into a broader patient population; that new collaborative partners will be found; that additional product opportunities will be established; or that that third parties on whom we depend will perform as anticipated.

Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment, including, without limitation, risks and uncertainties that are inherent in the development of complex biologics, the conduct of human clinical trials and the introduction of new products, including the timing, costs and outcomes of such trials, our ability to obtain necessary funding, regulatory approvals and expected qualifications, our dependence upon proprietary technology, our history of operating losses and accumulated deficits, our reliance on collaborative relationships and critical personnel, and current and future competition, as well as other risks described from time to time in filings we make with the Securities and Exchange Commission.  We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof.

Copyright 2012 Cardium Therapeutics, Inc.  All rights reserved.
For Terms of Use Privacy Policy, please visit

Cardium Therapeutics™, Generx®, Cardionovo™, Tissue Repair™, Gene Activated Matrix™, GAM™, Excellagen®, Excellarate™, Osteorate™, MedPodium®, Appexium®, Linee™, Alena™, Cerex®, D-Sorb™, Neo-Energy®, Neo-Carb Bloc®, Neo-Chill™, and Nutra-Apps® are trademarks of Cardium Therapeutics, Inc. or Tissue Repair Company.

SOURCE Cardium Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Smith Medical Partners Announces Logistics Agreement for Cardiums National Distribution of Excellagen™
2. Cardium Announces Closing of $5.0 Million Equity Financing
3. Cardium Regains Listing Compliance With NYSE Amex
4. Cardium Announces First International Marketing and Distribution Agreement for Commercialization of Excellagen™ in South Korea
5. Cardium Reports on Renewed Compliance With NYSE Amex Exchange Listing Guidelines
6. Cardium and SourceOne Global Partners Enter Into Cross-Strategic Equity Investment with Plans to Jointly Develop Nutritional Supplements and Medical Foods
7. Cardium to Present at the Rodman & Renshaw Annual Healthcare Investment Conference
8. Cardium Provides Update on Exchange Listing and Related Business Matters
9. Cardium to Present at Southern California Investor Conference
10. Cardium Announces Receipt of $1.1 Million in Funds from Philips Acquisition of Innercool Therapies
11. Cardium Presents Second Quarter 2011 Financial Results and Reports on Near-Term Milestones
Post Your Comments:
(Date:6/24/2016)... FRANCISCO, Calif. , June 24, 2016 /PRNewswire/ ... ), a biopharmaceutical company developing novel therapeutics for ... unmet needs, today announced the closing of its ... of common stock, at the public offering price ... in the offering were offered by GBT. GBT ...
(Date:6/24/2016)... Research and Markets has ... 2015-2025: Applications, Technologies, Forecasts" report to their ... Electronics, Smart Skin, Structural Health Monitoring, Composite Smart ... electronics involves electronic and/or electrical components and circuits ... structures such as vehicle bodies or conformally placed ...
(Date:6/24/2016)... , June 24, 2016  American Respiratory Labs (ARL), a ... now able to perform sophisticated lung assessments in patients, homes, thanks ... Inc. Patients are no longer limited to having ... PRO ® , ARL patients like Jeanne R. of ... the comfort of her own home. ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort to ... treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain management ... (SCD) is a disorder of the red blood cells, which can cause episodes of ...
(Date:6/24/2016)... ... 2016 , ... The Pulmonary Hypertension Association (PHA) learned during ... two significant new grants to support its work to advance research and patient ... recognizing patients, medical professionals and scientists for their work in fighting pulmonary hypertension ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of ... AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway ... call for a minimum wage raise to $12 an hour by 2020 and then adjusting ... restore the lost value of the minimum wage, assure the wage floor does not erode ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. ... articles published in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. ...
Breaking Medicine News(10 mins):